Publication | Closed Access

Cytoplasmic CD133 Expression is a Reliable Prognostic Indicator of Tumor Regression After Neoadjuvant Concurrent Chemoradiotherapy in Patients with Rectal Cancer

Gastrointestinal OncologyMedicinePathologyColorectal CancerCytoplasmic Cd133 ExpressionRectal CancerNeoadjuvant Concurrent ChemoradiotherapyCancer TreatmentOncologyRadiation OncologyTumor Biology